Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Hwang, K. Foon, P. Cheung, J. Pearson, R. Oldham (1984)
Selective antitumor effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma-associated antigen.Cancer research, 44 10
R. Herberman (1983)
Counterpoint: animal tumor models and their relevance to human tumor immunology.Journal of biological response modifiers, 2 1
Monoclonal antibodies in cancer ther
K. Foon, S. Sherwin, P. Abrams, D. Longo, M. Fer, H. Stevenson, J. Ochs, G. Bottino, C. Schoenberger, J. Zeffren (1984)
Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon.The New England journal of medicine, 311 18
M. Hanna, L. Peters (1981)
Morphological and functional aspects of active specific immunotherapy of established pulmonary metastases in guinea pigs.Cancer research, 41 10
V. Devita (1983)
Progress in cancer management. Keynote addressCancer, 51
R. Oldham (1985)
Biologicals and biological response modifiers: design of clinical trials.Journal of biological response modifiers, 4 2
J. Kirkwood, M. Ernstoff (1984)
Interferons in the treatment of human cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2 4
R. Smalley, J. Talmadge, R. Oldham, G. Thurman (1984)
The thymosins--preclinical and clinical studies with fraction V and alpha-I.Cancer treatment reviews, 11 1
M. Hanna, M. Key, R. Oldham (1983)
Biology of cancer therapy: some new insights into adjuvant treatment of metastatic solid tumors.Journal of biological response modifiers, 2 4
R. Oldham, R. Smalley (1983)
Immunotherapy: the old and the new.Journal of biological response modifiers, 2 1
Oldham Rk (1985)
Interferon: a model for future biologicals.Interferon, 6
Hewitt Hb (1983)
Second point: animal tumor models and their relevance to human tumor immunology.Journal of biological response modifiers, 2
R. Dillman, J. Beauregard, I. Royston, M. Zavanelli (1987)
Phase II trial of thymosin fraction 5 and thymosin alpha 1.Journal of biological response modifiers, 6 3
V. Devita (1983)
The james ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancerCancer, 51
(1903)
The Cure of CancerThe Indian Medical Gazette, 38
M. Hanna, M. Key (1982)
Immunotherapy of metastases enhances subsequent chemotherapy.Science, 217 4557
R. Oldham, G. Thurman, J. Talmadge, H. Stevenson, K. Foon (1984)
Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancerCancer, 54
R. Oldham (1985)
Biologicals and biological response modifiers: new approaches to cancer treatment.Cancer investigation, 3 1
(1982)
Monoclonal antibody therapy: Assessment by animal tumor models
Werner Rosenau (1981)
Lymphotoxin: properties, role and mode of action.International journal of immunopharmacology, 3 1
E. Rapp (1978)
Progress in Cancer Research and Therapy.Canadian Medical Association Journal, 118
(1982)
Biological Response Modifier Program
R. Oldham, A. Morgan, Clive Woodhouse, R. Schroff, P. Abrams, K. Foon (1984)
Monoclonal antibodies in the treatment of cancer: Preliminary observations and future prospectsMedical Oncology and Tumor Pharmacotherapy, 1
(1985)
Perspectives on the use of immuno-toxins in clinical medicine
H. Stevenson, J. Ochs, L. Halverson, R. Oldham, S. Sherwin, K. Foon (1984)
Recombinant alpha interferon in retreatment of two patients with pulmonary lymphoma. Dramatic responses with resolution of pulmonary complications.The American journal of medicine, 77 2
Oldham Rk (1983)
Biologicals: new horizons in pharmaceutical development.Journal of biological response modifiers, 2 3
R. Smalley, R. Oldham (1984)
Biological response modifiers: preclinical evaluation and clinical activity.Critical reviews in oncology/hematology, 1 3
R. Smalley (1986)
Interferon in the treatment of cancer.The Medical clinics of North America, Suppl
S. Sherwin, J. Knost, S. Fein, P. Abrams, K. Foon, J. Ochs, Carolyn Schoenberger, Maluish Ae, R. Oldham (1982)
A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients.JAMA, 248 19
P. Bunn, K. Foon, D. Ihde, D. Longo, J. Eddy, C. Winkler, S. Veach, J. Zeffren, S. Sherwin, R. Oldham (1984)
Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas.Annals of internal medicine, 101 4
B. Waksman (1979)
Overview: Biology of the Lymphokines
R. Oldham, K. Foon, A. Morgan, Clive Woodhouse, R. Schroff, P. Abrams, M. Fer, C. Schoenberger, M. Farrell, E. Kimball (1984)
Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2 11
(1979)
Active specific immunotherapy of residual micrometas-tasis: an evaluation of sources, doses and ratios of BCG with tumor cells
R. Dopfer, D. Niethammer, H. Peter, E. Kniep, D. Monner, P. Mühlradt (1984)
In vivo effects of interleukin 2 on lymphocyte subpopulations in a patient with a combined immunodeficiency.Immunobiology, 167 5
M. Key, J. Brandhorst, M. Hanna (1983)
Synergistic effects of active specific immunotherapy and chemotherapy in guinea pigs with disseminated cancer.Journal of immunology, 130 6
Michael Bernhard, K. Foon, Thomas Oeltmann, Marc Key, Kou Hwang, Gregory Clarke, Wayne Christensen, Lawrence Hoyer, Michael Hanna, Robert Oldham, M Laboratory (1983)
Guinea pig line 10 hepatocarcinoma model: characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain.Cancer research, 43 9
M. Cheever, P. Greenberg, A. Fefer (1984)
Potential for specific cancer therapy with immune T lymphocytes.Journal of biological response modifiers, 3 2
B. Zbar, I. Bernstein, G. Bartlett, M. Hanna, H. Rapp (1972)
Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis.Journal of the National Cancer Institute, 49 1
(1983)
Guinea pig 10 hepatocarcinoma model for monoclonal antibody serther-apy: In uiuo localization of a monoclonal antibody in normal and malignant tissues
K. Foon, R. Schroff, P. Bunn, D. Mayer, P. Abrams, M. Fer, J. Ochs, G. Bottino, S. Sherwin, D. Carlo (1984)
Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia.Blood, 64 5
R. Oldham (1984)
Biologicals and biological response modifiers: fourth modality of cancer treatment.Cancer treatment reports, 68 1
Biotherapy represents a new modality of cancer treatment. It utilizes biologicals and biological response modifiers in the treatment of cancer. Many of these substances are of “natural” origin emanating from mammalian cells as physiologic mediators of immune response and as substances active in the regulation of growth and maturation. With the advent of molecular biological techniques, hybridoma technology, and computer applications, it is now possible to prepare these biological substances in highly purified form and in large quantities for use as medicinals. The expertise required to apply these biotherapeutic approaches to the treatment of cancer often involves the use of immunological and/or molecular biological capabilities. Because of the rather specialized expertise needed to understand and apply these substances as anticancer approaches, those individuals with expertise in the application of chemotherapy to patients with cancer are not necessarily well prepared for the translation of biotherapy to the clinic. Biotherapeutic approaches are broad and involve a whole range of physiological responses inherent in cancer biology. The approaches necessary to bring these biotherapeutic capabilities to the clinic need to be considered carefully, and the use of new techniques and new methods of application should be encouraged so as not to inhibit these potentially powerful anticancer approaches. As natural mediators, many biologicals have much less inherent toxicity than the drugs previously used in systemic cancer therapy. Therefore, the systems for translating these substances from the laboratory to the clinic should be restructured for the rapid translation of biotherapy to the patient.
Journal of Cellular Physiology – Wiley
Published: Jan 1, 1986
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.